Standout Papers
- Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. (2003)
Immediate Impact
1 by Nobel laureates 12 from Science/Nature 70 standout
Citing Papers
Spin Hyperpolarization in Modern Magnetic Resonance
2023 Standout
Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy
2021 Standout
Works of Mark Klang being referenced
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
2003 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Mark Klang | 291 | 85 | 501 | 187 | 18 | 986 | |
| Eugenia Tsai | 165 | 149 | 310 | 147 | 25 | 1.0k | |
| Tadayoshi Kunitomo | 73 | 45 | 498 | 133 | 25 | 1.0k | |
| Loredana Mura | 146 | 43 | 263 | 146 | 15 | 766 | |
| H. Fletcher Starnes | 171 | 30 | 213 | 172 | 20 | 1.1k | |
| George Chan | 227 | 260 | 467 | 189 | 30 | 1.1k | |
| Carlo Mulas | 119 | 58 | 218 | 241 | 19 | 853 | |
| M. Treskes | 201 | 30 | 194 | 202 | 24 | 911 | |
| Mariele Dessì | 121 | 90 | 231 | 304 | 32 | 1.1k | |
| Nathalie Saidenberg-Kermanac’h | 112 | 37 | 283 | 159 | 28 | 1.1k | |
| Oleh M. Akchurin | 86 | 81 | 291 | 54 | 23 | 1.1k |
All Works
Login with ORCID to disown or claim papers
Loading papers...